SP-303T Applied to the Skin of Patients With Herpes Simplex Virus (HSV) Infection and AIDS Who Have Not Had Success With Acyclovir

Completed · Not applicable

Conditions studied: Herpes Simplex, HIV Infections

In brief

To evaluate the safety and tolerance of topically applied SP-303T in AIDS patients. To observe the effect of this drug on herpes simplex virus lesions in patients who have failed to heal in response to oral or intravenous acyclovir therapy. The lack of alternative treatments for herpes simplex virus infection in patients with AIDS and the development of resistance to acyclovir for patients requiring repeated treatment presents a therapeutic dilemma for physicians. SP-303T has good in vitro activity against resistant strains and offers a convenient and inexpensive means of drug administration in comparison to the use of intravenous medication.

Key facts

Study ID

NCT00002310

Run by

Shaman Pharmaceuticals

Last updated by the study team

2005-06-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients must have:
• HIV-1 infection.
• AIDS.
• Chronic mucocutaneous herpes simplex virus (HSV) infection, with one or more lesions unresponsive to oral acyclovir therapy.
• No uncontrolled infections other than HSV.
• Sufficient mental status to understand the purpose of the study and to comply with study requirements.
• Sufficient general health to be an outpatient and to come to the clinic for required follow-up visits.

You may not qualify if…

• Co-existing Condition:
• Patients with the following symptoms or conditions are excluded:
• Known hypersensitivity or allergy to citrus fruits, black currant berries, and rose hips.
• Any disease condition that, in the opinion of the investigator, would interfere with evaluation of the study drug, affect patient compliance, or place the patient at increased risk.
• Concurrent Medication:
• Excluded:
• Other unapproved investigational new drugs.
• Concurrent other therapy for herpes simplex virus (HSV) infection or medications with known activity against HSV.
• Required:
• A minimum of 10 days of prior oral acyclovir (at least 1 g daily) or 10 days of prior intravenous acyclovir (15 mg/kg daily).

Where it is running

• UCSF - San Francisco Gen Hosp — San Francisco, California, United States
• TheraFirst Med Ctrs Inc — Fort Lauderdale, Florida, United States
• Saint Luke's - Roosevelt Hosp Ctr — New York, New York, United States
• Univ of Utah School of Medicine — Salt Lake City, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.